Products
Moxifloxacin eye drops have been approved in many countries since 2008 (Vigamox). Moxifloxacin is also available in tablet form and as an infusion solution; see Moxifloxacin. Generic versions of the eye drops are registered.
Structure and properties
Moxifloxacin (C21H24FN3O4, Mr = 401.4 g/mol) is present in the eye drops as moxifloxacin hydrochloride, a slightly yellowish to yellow powder. It is an 8-methoxyfluoroquinolone with a diazabicyclononyl ring at the C7 position.
Effects
Moxifloxacin (ATC S01AX22) has bactericidal properties against Gram-positive and Gram-negative pathogens. The effects are due to inhibition of bacterial topoisomerase II (DNA gyrase) and topoisomerase IV. These enzymes play essential roles in bacterial DNA replication, transcription, and repair.
Indications
For local treatment of bacterial infections of the anterior segment of the eye.
Dosage
According to the professional information. Usually 1 drop is given into the eye(s) three times daily for four days. See also under Administration of eye drops.
Contraindications
Moxifloxacin is contraindicated in hypersensitivity. For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include local reactones on the eye such as a stinging, burning sensation on dropping in, redness, dry eyes, pain, and itching. Occasionally, headache and an altered taste sensation have been reported after dripping.
